{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:20:43Z","timestamp":1792844443602,"version":"4.5.0"},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,1,3]],"date-time":"2008-01-03T00:00:00Z","timestamp":1199318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate whether the cox\u20102 inhibitor celecoxib has antidepressant effects in bipolar disorder (BD) patients during depressive or mixed phases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We studied 28 DSM\u2010IV BD patients who were experiencing a depressive or mixed episode and were on a stable dose of a mood stabilizer or atypical antipsychotic medication. Subjects were randomized to receive 6 weeks of double\u2010blind placebo or celecoxib (400\u2009mg\/day) treatment. Current mood stabilizer or antipsychotic medication remained at the same doses during the trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Intention\u2010to\u2010treat analysis showed that the patients receiving celecoxib had lower Hamilton Depression Rating Scale (HamD) scores after 1 week of treatment compared to the patients receiving placebo, but this difference was not statistically significant (<jats:italic>p<\/jats:italic>\u2009=\u20090.09). The improvement in the first week of treatment was statistically significant when the analysis included only the subjects who completed the full 6\u2010week trial (<jats:italic>p<\/jats:italic>\u2009=\u20090.03). The two groups did not differ significantly on depressive or manic symptoms from the second week until the end of the trial. Celecoxib was well tolerated with the exception of two subjects who dropped out of the study due to rash.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our findings suggest that adjunctive treatment with celecoxib may produce a rapid\u2010onset antidepressant effect in BD patients experiencing depressive or mixed episodes. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.912","type":"journal-article","created":{"date-parts":[[2008,1,3]],"date-time":"2008-01-03T10:47:57Z","timestamp":1199357277000},"page":"87-94","source":"Crossref","is-referenced-by-count":244,"title":["Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double\u2010blind, randomized, placebo\u2010controlled study"],"prefix":"10.1002","volume":"23","author":[{"given":"Fabiano G.","family":"Nery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel S.","family":"Monkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Hatch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoela","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovana B.","family":"Zunta\u2010Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben\u00edcio N.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair C.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,3]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1978.tb02264.x"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.11.016"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(86)90040-5"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.10192"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2001.00311.x"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1006\/brbi.2000.0613"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286159603000229"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(99)00037-0"},{"key":"e_1_2_1_10_1","volume-title":"Structured Clinical Interview for DSM\u2010IV\u2010TR Axis I Disorders","author":"First MB","year":"2000"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200108093450607"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830130020004"},{"key":"e_1_2_1_13_1","first-page":"179","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Hamilton M","year":"1976"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001644"},{"key":"e_1_2_1_15_1","unstructured":"ICH Steering Committee. (5 February1998).ICH harmonized tripartite guideline: statistical principles for clinical trials (E9). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available athttp:\/\/www.ich.org\/cache\/compo\/276\u2010254\u20101. htmlAccessed May 12 2007."},{"key":"e_1_2_1_16_1","first-page":"1155","article-title":"Indomethacin and synthesis of brain prostaglandin E2 (PGE2) in vivo and in vitro","volume":"42","author":"Kleven MS","year":"1983","journal-title":"Fed Proc"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0262-1746(83)90048-3"},{"key":"e_1_2_1_18_1","first-page":"1","article-title":"The UKU side effects rating scale. A new comprehensive rating scale for psychotropic drugs and a cross\u2010sectional study of side effects in neuroleptic\u2010treated patients","volume":"334","author":"Lingjaerde O","year":"1978","journal-title":"Acta Psychiatr Scand"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790040059008"},{"key":"e_1_2_1_20_1","volume-title":"Statistical Analysis With Missing Data","author":"Little RJA","year":"1987"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.2.494"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.6.1029"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001805"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.2.210"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.146.3.365"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2005.11.006"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.02.024"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02104-0"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064135"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00000287"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07882-0"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200015040-00001"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1089\/089771502753754091"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0816"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7321.1123"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00219.x"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.912","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T11:07:42Z","timestamp":1699960062000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,3]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1002\/hup.912"],"URL":"https:\/\/doi.org\/10.1002\/hup.912","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,3]]}}}